← Leaderboards
Carri Geer
Novan, Inc.
$1,346,914
Attributed
$1,346,914
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $997.4K · FY2019–21$1M$750K$500K$250K$0
'19
'20
'21
Funding mix
By agency
NIH$1,346,914 · 1
By mechanism
R44$1,346,914 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Excision”
- Xinhua Li · Nano Terra, Inc.$26,433,300
- Shadi Dayeh · University Of California, San Diego$11,849,859
- Leah Johnson · Research Triangle Institute$10,876,154
- Deanna A Kulpa · Emory University$10,394,989
- Darren Baker · Mayo Clinic Rochester$7,821,986
- Jeffrey Benner · Drug Delivery Company, Llc, The$6,616,062
Research focus
ExcisionFormulationAnti-Viral EfficacyAdolescentCarcinogenicityFertilityCell Culture TechniquesCellsAnogenital Venereal WartsCervical Intraepithelial NeoplasiaCervix NeoplasmsChemical PropertyCarcinoma In SituAntiviral AgentsDesignDiagnosisDoseDrug CandidateEffective TherapyCervicalEnsureEnvironmentEvaluationFoundations
Grant awards (3)
Development of a nitric oxide-releasing antiviral gel for the treatment of cervical HPV infections and prevention of downstream malignancies in women$126,370
R44 · FY2021 · AI · contact PI
Development of a nitric oxide-releasing antiviral gel for the treatment of cervical HPV infections and prevention of downstream malignancies in women$997,413
R44 · FY2020 · AI · contact PI
Development of a nitric oxide-releasing antiviral gel for the treatment of cervical HPV infections and prevention of downstream malignancies in women$223,131
R44 · FY2019 · AI · contact PI